

On page 74, at the end of line 20, please insert --(SEQ ID NO: 12)--.  
On page 74, at the end of line 21, please insert --(SEQ ID NO: 13 )--.  
On page 75, at the end of line 5, please insert --(SEQ ID NO: 14)--.  
On page 75, at the end of line 6, please insert --(SEQ ID NO: 15)--.  
On page 77, at the end of line 6, please insert --(SEQ ID NO: 16)--.  
On page 77, at the end of line 7, please insert --(SEQ ID NO: 17)--.  
On page 77, at the end of line 18, please insert --(SEQ ID NO: 18)--.  
On page 78, at the end of line 10, please insert --(SEQ ID NO: 19)--.  
On page 78, at the end of line 11, please insert --(SEQ ID NO: 20)--.  
On page 78, at the end of line 14, please insert --(SEQ ID NO: 21)--.  
On page 78, at the end of line 15, please insert --(SEQ ID NO: 22)--.  
On page 78, at the end of line 31, after Humicola grisea, please insert --(SEQ  
ID NO: 23)--.  
On page 79, at the end of line 28, please insert --(SEQ ID NO: 24)--.  
On page 79, at the end of line 30, please insert --(SEQ ID NO: 25)--.  
On page 80, at the end of line 1, please insert --SEQ ID NO: 26)

Please insert the attached Sequence Listing (pages 1-9).


#### REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application, a 3.5" floppy disk containing the Sequence Listing and a Verified Statement by the undersigned.

The specification has been amended to provide SEQ ID NOS 1-26 for the sequences disclosed therein. This submission contains no new matter.

Respectfully submitted,

Date: August 9, 1999

  
Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123